Macrocyclics特约代理 - 代理品牌 - 上海钰博生物科技有限公司

Your present position: Home >> 代理品牌

新产品（仅供科研使用）

工作时间 :

周一~~周五

9:00 -18:00

在非工作时间，您可以通过邮件订购产品，订购时请写明详细联系方式，谢谢支持！

销售:18321282235

技术:021-60514606

传真:021-37680378

顾经理微信 扫一扫，关注我们

Macrocyclics特约代理

Product Introduction

Macrocyclics特约代理

Macrocyclics品牌名称：
Macrocyclics
Macrocyclics品牌Logo：

Macrocyclics官网：
https://www.macrocyclics.com/
Macrocyclics品牌介绍：
Macrocyclics – A short history and future directions.

Macrocyclics was founded in 1995 by Professor A. Dean Sherry as a result of his pioneering research in the development macrocyclic ligands for metal ions and their use as MRI contrast media. His ground breaking work stimulated worldwide interest by many researchers in the field and created a demand for macrocyclic chelating agents that were first prepared in the Sherry lab. Due to the challenging nature of the syntheses and purification, Professor Sherry would frequently receive requests for samples by his colleagues which eventually grew beyond the capacity of his UTD research lab to manage. The result was the birth of “Magnetic Resonance Solutions” in 1993 which was later renamed Macrocyclics in 1995.

During the early years the company’s revenue consisted of a few catalog products and several NIH and SBIR grants. The R&D funding provided through these grants enabled the company to generate new products and intellectual assets that stimulated growth in the field of nuclear medicine which relies heavily on chelating agents for imaging and therapy. This new found customer base rapidly generated projects that greatly expanded the catalog product line. Furthermore, many of these new customers were engaged in clinical development programs which demanded careful quality control in the production of chelating agents used in these studies. These stringent requirements prompted the launch of our custom cGMP manufacturing services in 2004.

In 2009 Macrocyclics was contracted by AREVA Med to perform the cGMP manufacturing of the chelating agent to be used in their clinical trial with Pb-212. During this collaboration, AREVA Med recognized the dynamic synergy that existed between the two organizations and the value that a merger would offer both companies. In October 2011 AREVA Med acquired Macrocyclics and in April 2016 we relocated to our newly constructed facility in in Plano Texas. The new facility is equipped with state of the art chemistry and biological laboratories as well as a radio-chemistry lab licensed to include all of the most popular radionuclides for PET imaging and therapeutic applications. This is an exciting time in our development and we are extremely grateful to you, our customers, for the many years of support that have made Macrocyclics successful.

Garry E. Kiefer

CEO and Director of Research

Macrocyclics，Inc.是定制螯合剂的制造商，致力于新的螯合化学平台的前沿开发，对于诊断和治疗药物的进步至关重要。专注领域cGMP螯合物合成，cGMP生物共轭服务，放射性药物开发，moelcular成像。

Macrocyclics相关产品

No.	品牌	货号	名称	规格
1	Macrocyclics	B-272	Maleimido-mono-amide-DOTA	50mg
2	Macrocyclics	B-275	Fmoc-L-Lys-mono-amide-DOTA-tris(t-Bu ester)	50mg
3	Macrocyclics	B-277	2-Aminoethyl-mono-amide-DOTA-tris(t-Bu ester)	100mg
4	Macrocyclics	B-301	p-NH2-Bn-DTPA-penta (t-Bu ester)	1g
5	Macrocyclics	B-351	p-NH2-Bn-CHX-A"-DTPA	100mg
6	Macrocyclics	B-365	DTPA-tetra (t-Bu ester)	500mg
7	Macrocyclics	B-616	NO2A-Butyne-bis (t-Butyl ester)	100mg
8	Macrocyclics	B-622	Maleimido-mono-amide-NOTA	100mg
9	Macrocyclics	B-628	NO2A-Azide	100mg
10	Macrocyclics	S-100	Bifunctional Starter Pack	50mg
11	Macrocyclics	M-090	TACN	1g
12	Macrocyclics	M-150	DOTP	5g
13	Macrocyclics	M-190	DiAmSar	100mg
14	Macrocyclics	M-220	CB-TE2A	100mg
15	Macrocyclics	M-145	Tm-DOTA	500mg